NCT06908252 (MAPS PrEP) is a Phase 4 clinical trial of Pre-Exposure Prophylaxis (PrEP) in HIV Infection, sponsored by Duke University.

Who is sponsoring NCT06908252?

NCT06908252 is sponsored by Duke University.

What drugs are being tested in NCT06908252?

Interventions in NCT06908252: Pre-Exposure Prophylaxis (PrEP).

What condition does NCT06908252 study?

NCT06908252 studies HIV Infection.

Is NCT06908252 still recruiting?

NCT06908252 is currently recruiting now. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT06908252: MAPS PrEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MAPS PrEP Van Study

Recruiting now Phase 4 Last updated 20 January 2026

What this trial tests

Phase 4 trial testing Pre-Exposure Prophylaxis (PrEP) in HIV Infection in 20 participants. Currently enrolling.

Timeline

17 September 2025

Primary endpoint
30 June 2026

31 July 2026

Quick facts

Lead sponsor	Duke University
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	17 September 2025
Primary completion	30 June 2026
Estimated completion	31 July 2026
Sites	1 location across United States

Drugs / interventions tested

Pre-Exposure Prophylaxis (PrEP) — full drug profile →

Conditions studied

HIV Infection — all drugs for HIV Infection →

Sponsor

Duke University

Who can join

18 and older, any sex, with HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV Infection

Currently open trials in the same condition.

NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i · NA · recruiting
NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) · Phase 1 · recruiting
NCT06716450 — Multiplo Tp/HIV Self-Test · NA · recruiting
NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
NCT07031063 — Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience · Phase 4 · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06908252 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908252.